Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Metagenomi (MGX) EBITDA Margin (2023 - 2025)

Metagenomi (MGX) has disclosed EBITDA Margin for 3 consecutive years, with 578.85% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 32581.0% to 578.85% in Q4 2025 year-over-year; TTM through Dec 2025 was 350.33%, a 20260.0% decrease, with the full-year FY2025 number at 350.33%, down 20260.0% from a year prior.
  • EBITDA Margin was 578.85% for Q4 2025 at Metagenomi, down from 235.52% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 53.61% in Q2 2024 to a low of 608.84% in Q1 2025.
  • A 3-year average of 246.32% and a median of 206.55% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: skyrocketed 6268bps in 2024, then tumbled -38186bps in 2025.
  • Metagenomi's EBITDA Margin stood at 153.5% in 2023, then crashed by -65bps to 253.05% in 2024, then plummeted by -129bps to 578.85% in 2025.
  • Per Business Quant, the three most recent readings for MGX's EBITDA Margin are 578.85% (Q4 2025), 235.52% (Q3 2025), and 236.78% (Q2 2025).